Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Envoy Medical (COCH) EBIT Margin (2022 - 2025)

Envoy Medical's EBIT Margin history spans 4 years, with the latest figure at 13590.48% for Q3 2025.

  • For Q3 2025, EBIT Margin fell 470833.0% year-over-year to 13590.48%; the TTM value through Sep 2025 reached 9824.04%, down 53109.0%, while the annual FY2024 figure was 8558.22%, 274461.0% down from the prior year.
  • EBIT Margin for Q3 2025 was 13590.48% at Envoy Medical, down from 6500.0% in the prior quarter.
  • Across five years, EBIT Margin topped out at 156.5% in Q2 2023 and bottomed at 22597.79% in Q4 2022.
  • The 4-year median for EBIT Margin is 8277.97% (2024), against an average of 8692.56%.
  • The largest annual shift saw EBIT Margin skyrocketed 1089631bps in 2023 before it tumbled -699056bps in 2024.
  • A 4-year view of EBIT Margin shows it stood at 22597.79% in 2022, then soared by 48bps to 11701.48% in 2023, then grew by 7bps to 10830.95% in 2024, then fell by -25bps to 13590.48% in 2025.
  • Per Business Quant, the three most recent readings for COCH's EBIT Margin are 13590.48% (Q3 2025), 6500.0% (Q2 2025), and 11102.17% (Q1 2025).